Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors

Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors

In recent years, immunotherapy has made breakthroughs in the field of malignant tumors, and more and more novel immune checkpoint inhibitors have been developed, revolutionizing the first-line, second-line and post-line treatment options for malignant tumors. Tislelizumab is a domestically developed...

Full description

Bibliographic Details
Main Authors: LUO Xiangchong, WANG Zhouqing, LI Qiongyan, MAO Guibing, AN Le, ZHU Jiahong, TAO E'hong, SUN Lifei, WANG Shengfei, LI Gaofeng
Format: Article
Language:zho
Published: Editorial Office of Medical Journal of Peking Union Medical College Hospital 2022-07-01
Series:Xiehe Yixue Zazhi
Subjects:
malignant tumor
pd-1 inhibitor
tislelizumab
immunotherapy
Online Access:https://xhyxzz.pumch.cn/en/article/doi/10.12290/xhyxzz.2021-0691

Internet

https://xhyxzz.pumch.cn/en/article/doi/10.12290/xhyxzz.2021-0691

Similar Items